Duopharma earnings rise to RM88.56mil


PETALING JAYA: Duopharma Biotech Bhd posted a net profit of RM88.56mil in the nine-month period to Sept 30, 2026 (9M26), as compared to RM68.42mil in the year-ago period, due to strong profit margins that offset a weaker topline.

According to the pharmaceutical group’s results filing with Bursa Malaysia, profit margins were supported by a more favourable product mix and lower imported active pharmaceutical ingredient costs amid the strengthening of the ringgit.

Revenue in 9M26 was RM692.29mil, down from RM707.01mil in 9M25, primarily attributable to the normalisation of public sector insulin sales following the exceptional sales recorded in the first half of 2025.

In the third quarter alone, the group recorded a higher net profit of RM27.98mil as compared to RM22.57mil in the year-ago quarter. Quarterly revenue dipped to RM210.05mil from RM222.49mil in the previously comparative quarter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Malaysia focuses on trade expansion, friendly relations to drive economic growth
LTAT: BPlant bidders met GLC or Bumiputera criteria
Is MR DIY overexpanding?
Sports Toto confident of strengthening NFO market position
PETRA: 2027-2035 electricity reserve margin projected at 24-27%
Willownex secures RM28.8mil security systems contracts in Singapore
Citaglobal seeks full ownership of German WTE engineering firm LAWI for RM5mil
UEM Sunrise upbeat on prospects after stronger 9M26 earnings
JS Solar secures RM30mil rooftop solar, battery storage contract
Manforce secures RM9.4mil foreign worker management contract

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read